KR20220035925A - Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 - Google Patents

Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 Download PDF

Info

Publication number
KR20220035925A
KR20220035925A KR1020227004829A KR20227004829A KR20220035925A KR 20220035925 A KR20220035925 A KR 20220035925A KR 1020227004829 A KR1020227004829 A KR 1020227004829A KR 20227004829 A KR20227004829 A KR 20227004829A KR 20220035925 A KR20220035925 A KR 20220035925A
Authority
KR
South Korea
Prior art keywords
carcinoma
leukemia
cancer
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227004829A
Other languages
English (en)
Korean (ko)
Inventor
셸던 엔. 크레인
보위 린 트루옹
아바스 아브도리
장 프랑수아 트루콩
카메론 블랙
스테판 도리치
리 페이더
스테파니 라노이스
폴 존스
미구엘 생 옹게인
오드리 피카르드
키루스 엠. 락베이
Original Assignee
리페어 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2019/051539 external-priority patent/WO2020087170A1/en
Application filed by 리페어 세라퓨틱스 인크. filed Critical 리페어 세라퓨틱스 인크.
Publication of KR20220035925A publication Critical patent/KR20220035925A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227004829A 2019-07-22 2020-07-22 Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 Ceased KR20220035925A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962877177P 2019-07-22 2019-07-22
US62/877,177 2019-07-22
CAPCT/CA2019/051539 2019-10-30
PCT/CA2019/051539 WO2020087170A1 (en) 2018-10-30 2019-10-30 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PCT/CA2020/051014 WO2021012049A1 (en) 2019-07-22 2020-07-22 Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20220035925A true KR20220035925A (ko) 2022-03-22

Family

ID=74192632

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004829A Ceased KR20220035925A (ko) 2019-07-22 2020-07-22 Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체

Country Status (16)

Country Link
US (1) US20220185809A1 (https=)
EP (1) EP4003993A4 (https=)
JP (2) JP7617076B2 (https=)
KR (1) KR20220035925A (https=)
CN (1) CN114174292B (https=)
AU (1) AU2020317381A1 (https=)
BR (1) BR112022000431A2 (https=)
CA (1) CA3148278A1 (https=)
CO (1) CO2022001853A2 (https=)
CR (1) CR20220068A (https=)
EC (1) ECSP22012347A (https=)
IL (1) IL289763A (https=)
MX (1) MX2022000854A (https=)
PH (1) PH12022550156A1 (https=)
UA (1) UA129807C2 (https=)
WO (1) WO2021012049A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210281A (es) 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
CA3164203A1 (en) * 2019-12-11 2021-06-17 Repare Therapeutics Inc. Use of atr inhibitors in combination with parp inhibitors
BR112023022481A2 (pt) * 2021-04-28 2024-02-15 Repare Therapeutics Inc Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica
MX2023014302A (es) * 2021-06-04 2024-02-28 Repare Therapeutics Inc Formas cristalinas, composiciones que contienen las mismas y métodos para su uso.
KR20240041354A (ko) * 2021-07-27 2024-03-29 릿츠뜨 메디시네스 엘티디 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도
CN113856764B (zh) * 2021-10-29 2022-11-01 华中科技大学 一种过渡金属催化剂及其制备方法和应用
CN116099390B (zh) * 2022-11-14 2024-07-23 石河子大学 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用
WO2024211696A1 (en) * 2023-04-07 2024-10-10 Biogen Ma Inc. 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
WO2025067111A1 (zh) * 2023-09-27 2025-04-03 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025181153A1 (en) * 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795573B1 (en) * 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
JP5889875B2 (ja) * 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
ES2951688T3 (es) * 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
EP2755962B1 (en) * 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
RS61688B1 (sr) * 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
JP6873145B2 (ja) * 2016-01-14 2021-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
CR20210281A (es) * 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.

Also Published As

Publication number Publication date
JP2022541825A (ja) 2022-09-27
JP2025061048A (ja) 2025-04-10
MX2022000854A (es) 2022-02-10
ECSP22012347A (es) 2022-03-31
CA3148278A1 (en) 2021-01-28
CR20220068A (es) 2022-06-30
AU2020317381A1 (en) 2022-02-10
BR112022000431A2 (pt) 2022-03-03
UA129807C2 (uk) 2025-08-06
WO2021012049A8 (en) 2021-04-15
EP4003993A4 (en) 2023-01-18
EP4003993A1 (en) 2022-06-01
CN114174292B (zh) 2024-06-18
PH12022550156A1 (en) 2023-05-08
WO2021012049A1 (en) 2021-01-28
CO2022001853A2 (es) 2022-03-29
US20220185809A1 (en) 2022-06-16
JP7617076B2 (ja) 2025-01-17
IL289763A (en) 2022-03-01
CN114174292A (zh) 2022-03-11
JP7758895B2 (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
JP7758895B2 (ja) Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
US12264155B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
EP4126879B1 (en) N-phenyl substituted indole derivatives as myt1 inhibitors for the treatment of cancer
US12435090B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US20230158022A1 (en) Methods of using myt1 inhibitors
WO2023050007A1 (en) N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
RU2806857C2 (ru) Соединения, фармацевтические композиции, способы приготовления соединений и их применение в качестве ингибиторов киназы atr
EA047254B1 (ru) Производные замещенного 2-морфолинопиридина в качестве ингибиторов atr-киназы
HK40070621A (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
HK40070621B (zh) 作为atr激酶抑制剂的取代的2-吗啉代吡啶衍生物
EA050141B1 (ru) Соединения, фармацевтические композиции, а также способы получения соединений и их применения
EA052456B1 (ru) Соединения, фармацевтические композиции, а также способы получения соединений и их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601